The impact of interleukin serum levels on the prognosis of patients undergoing venoarterial extracorporeal membrane oxygenation.
cardiac failure
extracorporeal life support
intensive care
resuscitation
Journal
Artificial organs
ISSN: 1525-1594
Titre abrégé: Artif Organs
Pays: United States
ID NLM: 7802778
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
23
10
2019
revised:
31
12
2019
accepted:
07
02
2020
pubmed:
12
2
2020
medline:
3
6
2021
entrez:
12
2
2020
Statut:
ppublish
Résumé
Extracorporeal life support is increasingly used in the treatment of patients presenting with cardiogenic shock or in need of cardiopulmonary resuscitation. Identifying therapeutic targets and factors associated with the prognosis are highly desirable. The present study analyzed the impact of interleukin 6 and 8 on the outcome of patients undergoing venoarterial extracorporeal membrane oxygenation (VA ECMO). Interleukin 6 and 8 serum levels of 329 patients were analyzed prior to, on days 1 and 5 of VA ECMO therapy. Interleukin 6 and 8 serum levels of surviving and nonsurviving patients were compared. At time points with significant differences, receiver operating characteristics and cutoff levels were analyzed to determine the prognostic value of interleukin serum levels. Survival analysis was performed to compare patients above and below cutoff levels. Interleukin 6 serum levels were significantly elevated in nonsurviving patients prior to VA ECMO initiation. Interleukin 6 and 8 serum levels in nonsurviving patients were significantly elevated on day 1 of VA ECMO. Receiver operating characteristics analysis revealed significant prognostic impact of interleukin 6 and 8 on day 1 of VA ECMO (AUC 0.70 and 0.72). Survival analysis comparing patients above and below the cutoff showed a 1-year survival of 32.6% for IL6 and 20.8% for IL8 above, as well as 66.9% for IL6 and 61.9% for IL8 below the cutoff (P < .05). Interleukin 6 and 8 serum levels demonstrated prognostic value early in VA ECMO therapy. The technical applicability of interleukin reduction raises interest in interleukins 6 and 8 as therapeutic targets.
Substances chimiques
Biomarkers
0
Interleukin-6
0
Interleukin-8
0
Interleukins
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
837-845Informations de copyright
© 2020 International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc.
Références
ECLS Registry Report. International summary. Extracorporeal life support organization. Ann Arbor (MI). [Accessed 2018 Jan 18]. Available from: https://www.elso.org/Registry/Statistics/InternationalSummary.aspx
Ouweneel DM, Schotborgh JV, Limpens J, Sjauw KD, Engström AE, Lagrand WK, et al. Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. Intensive Care Med. 2016;42:1922-34.
Gray BW, Haft JW, Hirsch JC, Annich GM, Hirschl RB, Bartlett RH. Extracorporeal life support: experience with 2,000 patients. ASAIO J. 2015;6:2-7.
Aubin H, Petrov G, Dalyanoglu H, Richter M, Saeed D, Akhyari P, et al. Four-year experience of providing mobile extracorporeal life support to out-of-center patients within a suprainstitutional network-Outcome of 160 consecutively treated patients. Resuscitation. 2017;121:151-7.
Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL. Sepsis and septic shock. Nat Rev Dis Primers. 2016;30:16045.
Ma LI, Zhang H, Yin Y-L, Guo W-z, Ma Y-q, Wang Y-b, et al. Role of interleukin-6 to differentiate sepsis from non-infectious systemic inflammatory response syndrome. Cytokine. 2016;88:126-35.
Tanaka T, Narazaki M, Kishimoto T. IL-6 in Inflammation, Immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6:a016295.
Day JR, Taylor KM. The systemic inflammatory response syndrome and cardiopulmonary bypass. Int J Surg. 2005;3:129-40.
Fanola CL, Morrow DA, Cannon CP, Jarolim P, Lukas MA, Bode C, et al. Interleukin-6 and the risk of adverse outcomes in patients after an acute coronary syndrome: observations from the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) trial. J Am Heart Assoc. 2017;6:e005637.
Ellulu MS, Patimah I, Khaza'ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13:851-63.
Steinbach G, Bölke E, Schulte am Esch J,Peiper M, Zant R, Schwarz A, et al. Comparison of whole blood interleukin-8 and plasma interleukin-8 as a predictor for sepsis in postoperative patients. Clin Chim Acta. 2007;378:117-21.
McILwain RB, Timpa JG, Kurundkar AR, Holt DW, Kelly DR, Hartman YE et al. Plasma concentrations of inflammatory cytokines rise rapidly during ECMO-related SIRS due to the release of preformed stores in the intestine. Lab Invest. 2010;90:128-39.
Han MK, Quibrera PM, Carretta EE, Barr RG, Bleecker ER, Bowler RP, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5:619-26.
Dennis M, McCanny P, D’Souza M, Forrest P, Burns B, Lowe DA, et al. Extracorporeal cardiopulmonary resuscitation for refractory cardiac arrest: a multicentre experience. Int J Cardiol. 2017;15:131-6.
Wong JK, Melvin AL, Joshi DJ, Lee CY, Archibald WJ, Angona RE, et al. Cannulation-related complications on veno-arterial extracorporeal membrane oxygenation: prevalence and effect on mortality. Artif Organs. 2017;41:827-34.
Davies MG, Hagen P-O. Systemic inflammatory response syndrome. Br J Surg. 1997;84:920-35.
Shi J, Chen Q, Yu W, Shen J, Gong J, He C, et al. Continuous renal replacement therapy reduces the systemic and pulmonary inflammation induced by venovenous extracorporeal membrane oxygenation in a porcine model. Artif Organs. 2014;38:215-23.
Millar JE, Fanning JP, McDonald CI, McAuley DF, Fraser JF. The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology. Crit Care. 2016;20:387.
Risnes I, Wagner K, Ueland T, Mollnes T, Aukrust P, Svennevig J. Interleukin-6 may predict survival in extracorporeal membrane oxygenation treatment. Perfusion. 2008;23:173-8.
Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamua M. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine. 2005;29:169-75.
Feng M, Sun T, Zhao Y, Zhang H. Detection of serum interleukin-6/10/18 levels in sepsis and its clinical significance. J Clin Lab Anal. 2016;30:1037-43.
Barre M, Behnes M, Hamed S, Pauly D, Lepiorz D, Lang S, et al. Revisiting the prognostic value of monocyte chemotactic protein 1 and interleukin-6 in the sepsis-3 era. J Crit Care. 2018;43:21-8.
Jawa RS, Kulaylat MN, Baumann H, Dayton MT. What is new in cytokine research related to trauma/critical care. J Intensive Care Med. 2006;21:63-85.
Egorina EM, Sovershaev MA, Hansen JB. The role of tissue factor in systemic inflammatory response syndrome. Blood Coagul Fibrinolysis. 2011;22:451-6.
Levi M, van der Poll T. Coagulation and sepsis. Thromb Res. 2017;149:38-44.
Levi M, van der Poll T. Endothelial injury in sepsis. Intensive Care Med. 2013;39:1839-42.
Werdan K. Do not get in RAGE in cardiogenic shock: it is detrimental! Crit Care Med. 2012;40:1669-70.
Krüttgen A, Rose John S. Interleukin-6 in sepsis and capillary leakage syndome. J Interferone Cytokine Res. 2012;32:60-5.
Pool R, Gomez H, Kellum JA. Mechanisms of organ dysfunction in sepsis. Crit Care Clin. 2018;34:63-80.
Roth C, Schrutka L, Binder C, Kriechbaumer L, Heinz G, Lang IM, et al. Liver function predicts survival in patients undergoing extracorporeal membrane oxygenation following cardiovascular surgery. Crit Care. 2016;20:57.
Schmidt M, Burrell A, Roberts L, Bailey M, Sheldrake J, Rycus PT, et al. Predicting survival after ECMO for refractory cardiogenic shock: the survival after veno-arterial-ECMO (SAVE)-score. Eur Heart J. 2015;36:2246-56.
Wengenmayer T, Duerschmied D, Graf E, Chiabudini M, Benk C, Mühlschlegel S, et al. Development and validation of a prognostic model for survival in patients treated with venoarterial extracorporeal membrane oxygenation: the PREDICT VA-ECMO score. Eur Heart J Acute Cardiovasc Care. 2018;8:350-9.
Park JT, Lee H, Kee YK, Park S, Oh HJ, Han SH, et al. High-dose versus conventional-dose continuous venovenous hemodiafiltration and patient and kidney survival and cytokine removal in sepsis-associated acute kidney injury: a randomized controlled trial. Am J Kidney Dis. 2016;68:599-608.
Bengsch S, Boos KS, Nagel D, Seidel D, Inthorn D. Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: clinical results of a pilot study. Shock. 2005;23:494-500.
Schädler D, Pausch C, Heise D, Meier-Hellmann A, Brederlau J, Weiler N, et al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial. PLoS ONE. 2017;12:e0187015. https://doi.org/10.1371/journal.pone.0187015.
Kirkpatrick AW, Roberts DJ, Faris PD, Ball CG, Kubes P, Tiruta C, et al. Active negative pressure peritoneal therapy after abbreviated laparotomy: the intraperitoneal vacuum randomized controlled trial. Ann Surg. 2015;262:38-46.
Bernardi MH, Rinoesl H, Dragosits K, Ristl R, Hoffelner F, Opfermann P, et al. Effect of hemoadsorption during cardiopulmonary bypass surgery - a blinded, randomized, controlled pilot study using a novel adsorbent. Crit Care. 2016;20:96.